Pharma IQ Members

Clinical Supply
30 results
of 3
Contributor: Pharma IQ
Posted: 14/07/2017
Pharma IQ
Artificial intelligence could herald a new era for drug development but caution remains about how revolutionary its impact will actually be Full Content »
Contributor: Pharma IQ
Posted: 14/07/2017
Pharma IQ
If your company was handed with a notice for a clinical trial inspection right now, what would the reaction be? A feeling of calm confidence or a rush of slight concern? In this ebook Pharma IQ compared the perspectives of a Clinical Research Organisation (CRO) to that of a sponsor concerning the burning topic of trial master file inspection readiness. Full Content »
Contributor: Editorial Staff
Posted: 29/03/2017
mmn logo
It's true: Many confuse the process of getting ideas with the agonizing realities of putting them to work.Lack of creativity is not the problem in most organizations. Great ideas almost always abound.The real problem is converting an idea, which is just a good intention, into operational reality.Indeed, a powerful new idea can kick around unused in Full Content »
Contributor: Pharma IQ
Posted: 17/02/2017
Pharma IQ
Contributor: Social Monsters.org
Posted: 14/02/2017
default profile icon
After years of resistance, the health care and pharmaceutical industries are now accelerating full steam towards the cloud. In fact, the global health care cloud computing market, valued at $4.5 billion in 2016, will reach $9.5 billion by 2020. Here are the dominant benefits that are drawing these giants to the cloud. Full Content »
Contributor: George Clinical Representative
Posted: 24/01/2017
Georger
The field of clinical research is growing and advancing thanks to technological advances like real time data collection and analysis, health care applications, and wearable technologies. The clinical trial industry is seeing huge strides thanks to these digital and technological advances that are making studies more efficient, faster, safer, and garnering more participants Full Content »
Contributor: Pharma IQ
Posted: 17/01/2017
Pharma IQ
The melanoma pipeline, which is typically underserved due to stubborn R&D challenges, is being praised for its levels of innovation as of late with 579 programs active across all stages of development, with 226 first-in-class programs in the pipeline, acting on 138 distinct first-in-class molecular targets. This accounts for 38% of all programs with a disclosed molecular target and reflects the high degree of innovation in this indication, according to business intelligence provider GBI Research. Full Content »
Contributor: Pharma IQ
Posted: 20/12/2016
Pharma IQ
The last quarter of 2016 was certainly not short of activity with a £84 million pharma fine issued in regards to drug pricings, an investigation into a suspected supply chain breach and numerous therapeutic approvals. Full Content »
Contributor: George Clinical Representative
Posted: 21/10/2016
Georger
George Clinical’s parent organisation, The George Institute for Global Health and its TEXTCARE application, has been named a top 10 finalist in this year’s Google Impact Challenge. With a top prize of AUD $750,000, The George Institute has the opportunity to use its proven text messaging platform to tackle chronic disease on a global scale. Full Content »
Contributor: George Clinical Representative
Posted: 11/10/2016
Georger
As the costs and complexities of running clinical trials increase, so does the impetus, indeed obligation, to invest in fully integrated eSystems that are essential to simplifying the overall clinical trial process. Full Content »
Contributor: Dr. Andrea Zobel
Posted: 04/10/2016
Andrea
Currently, two trends are in focus for the clinical trial supply chain: patient centricity and the usage of the Internet of Things (IoT) in clinical trials. Both components are driven by the need to shorten clinical development timelines, reduce costs and improve data quality. The clinical supply chain can contribute significantly to these objectives. Full Content »
30 results
of 3
Contributor: Pharma IQ
Posted: 17/02/2017
Pharma IQ
Contributor: Pharma IQ
Posted: 14/07/2017
Pharma IQ
If your company was handed with a notice for a clinical trial inspection right now, what would the reaction be? A feeling of calm confidence or a rush of slight concern? In this ebook Pharma IQ compared the perspectives of a Clinical Research Organisation (CRO) to that of a sponsor concerning the burning topic of trial master file inspection readiness. Full Whitepaper »